25 Apr 2018
Marta Enrich

EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018

London, April 25th, 2018 – EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018. The 12-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented for the first time at CX Symposium 2018 at the DCB session on April 24th. Main objective was […]

read more
Share this
08 Mar 2018
Marta Enrich

EFFPAC-RCT 12-month results will be presented for the first time at CX Symposium 2018

Barcelona, March 8th, 2018 – EFFPAC-RCT 12-month results will be presented for the first time on April 24th at CX Symposium 2018 The 12-month results from the full clinical cohort of the EFFPAC randomized control trial (RCT), comparing the Luminor DCB (iVascular) to POBA, are going to be presented for the first time at Charing […]

read more
Share this
13 Feb 2018
Marta Enrich

iVascular Luminor DCB proves to be the best!

Barcelona, February 14th, 2018 – iVascular Luminor DCB proves to be the best! The EFFPAC 6-month results have been presented by Prof. Dierk Scheinert (Park-Krankenhaus Leipzig, Germany) at the opening of the LINC 2018 main session dedicated to latest results with new technologies for femoropopliteal obstructions. EFFPAC is a Randomized Controlled Study comparing the Luminor […]

read more
Share this
28 Dec 2017
Marta Enrich

Oceanus 35, PTA balloon dilatation catheter receives CE Mark Approval for new catheter length of 200 cm.

Barcelona, December 28th, 2017- Oceanus 35, PTA balloon dilatation catheter receives CE Mark Approval for new catheter length of 200 cm. iVascular is pleased to announce that its Oceanus 35 PTA balloon dilatation catheter has received CE mark approval for its new usable catheter length of 200cm. With this, iVascular offers a complete portfolio including […]

read more
Share this
18 Dec 2017
Marta Enrich

Luminor DCB received approval for commercialization in New Zealand

Barcelona, December 18th, 2017- Luminor DCB has received approval for commercialization in New Zealand. IVascular is pleased to announce that the Luminor Drug Coated Balloon (DCB) indicated for peripheral arteries, has received approval for commercialization in New Zealand. Luminor is a Paclitaxel Coated Balloon specifically designed for dilatation of stenosis located in the iliac, femoral, […]

read more
Share this
05 Dec 2017
Marta Enrich

iVascular starts partnership with TD Medical.

Barcelona, December 5th, 2017- iVascular starts partnership with TD Medical. In September of this year, TD Medical announced that in 2018 they will become exclusive distributors of iVascular in Netherlands. TD Medical stated “IVascular fully fits our objectives. They offer us the space to adapt to the dynamic changes in Dutch healthcare. This offers many […]

read more
Share this
04 Dec 2017
Anastasia Perebeynos

Oceanus 14 Pro, PTA balloon catheter receives CE Mark Approval

    http://www.ivascular.global/wp-content/uploads/2015/09/iVascular_therapies_for_living.png
  • Coronary and peripheral news

Barcelona, December 4th, 2017- Oceanus 14 Pro, PTA balloon catheter receives CE Mark Approval. iVascular is pleased to announce the release of the new Oceanus 14 Pro PTA balloon catheter, which has received CE Mark Approval to dilate stenoses in femoral, popliteal, and infrapopliteal arteries, and to treat obstructive lesions in arteriovenous dialysis fistulae. Oceanus 14 […]

read more
Share this
29 Sep 2017
Anastasia Perebeynos

The T.I.N.T.I.N. trial evaluating the combined therapy of Luminor DCB and iVolution SX stent

    http://www.ivascular.global/wp-content/uploads/2015/09/iVascular_therapies_for_living.png
  • Coronary and peripheral news

Barcelona, September 25th, 2017 – iVascular S.L.U. has announced the initiation of the T.I.N.T.I.N. trial, evaluating the combined therapy of Luminor drug coated balloon (DCB) and iVolution self-expandable stent. T.I.N.T.I.N. study is prospective, investigator-initiated, non-randomized, multi-center trial, investigating the 12 months safety and efficacy of combined Luminor DCB and iVolution self-expandable stent in TASC C […]

read more
Share this
21 Sep 2017
Anastasia Perebeynos

Luminor 14m has received the Canadian Medical Device License

    http://www.ivascular.global/wp-content/uploads/2015/09/iVascular_therapies_for_living.png
  • Coronary and peripheral news

Barcelona, September 21th, 2017 – iVascular S.L.U. has announced that Luminor 14m, the Drug Coated Balloon (DCB) indicated for below the knee BTK arteries, has received the Canadian Medical Device License (MDL). Luminor 14m is a Paclitaxel Coated Balloon specifically designed for BTK indications, thanks to its extra low crossing profile combined with TransferTechTM, iVascular […]

read more
Share this
20 Sep 2017
Anastasia Perebeynos

iVascular SLU received approval for selling its coronary and peripheral products in India

    http://www.ivascular.global/wp-content/uploads/2015/09/iVascular_therapies_for_living.png
  • Coronary and peripheral news

Barcelona, September 20th, 2017 – iVascular SLU announced today that it has received approval for selling its coronary and peripheral products in India. Indian medical devices market is the 4th largest in Asia and part of the global top 20. “iVascular product portfolio was created with the latest technologies to improve patient’s outcomes and provide physicians with […]

read more
Share this
18 Sep 2017
Anastasia Perebeynos

iVascular EffPAC 6 Months Outstanding Data Presented at CIRSE 2017 DCB Session

    http://www.ivascular.global/wp-content/uploads/2015/09/iVascular_therapies_for_living.png
  • Coronary and peripheral news

Copenhagen – September 18, 2017 – iVascular SLU data announced today, demonstrate the efficacy of the Luminor drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The 6 months results from the full clinical cohort of the EffPAC randomized study were presented in the DCB session at the Cardiovascular and Interventional Radiological Society of Europe […]

read more
Share this
30 Aug 2017
Anastasia Perebeynos

iVascular & Braile to partner to develop structural heart solutions

    http://www.ivascular.global/wp-content/uploads/2015/09/iVascular_therapies_for_living.png
  • Coronary and peripheral news

June 19th, 2017 iVascular S.L.U. and Braile Biomedica are pleased to announce that they have entered into a joint-venture agreement, to develop innovative structural heart solutions. The new entity, based in Barcelona (Spain), will be managed by Mrs. Patricia Braile, CEO of Braile Biomedica, as President, and by Mr. Lluis Duocastella, CEO of iVascular SLU, […]

read more
Share this

© 2018 iVascular SLU. All rights reserved. Legal Notice | Terms of use

We use cookies to guarantee the best experience in your navigation. If you continue browsing consider to accept the use of cookies. More information

ACEPTAR
Aviso de cookies